Skip to content
Search

Latest Stories

Scottish community pharmacies global sum remuneration increased by 6 per cent to £220 million for 2023-24

Following discussions with Community Pharmacy Scotland, the Scottish government has agreed to a six per cent rise in the global fund allocation for community pharmacies in 2023-24, bringing the total remuneration to approximately £219.5 million.

A finalised agreement has been reached with Community Pharmacy Scotland for a one-year funding package for the financial year 2023-24, as stated in a Scottish government circular distributed to community pharmacy contractors and NHS Boards on August 4.


The circular said this settlement will lead to the most substantial increment ever approved for the community pharmacy network.

“The global sum remuneration will be £219.533 million, signifying a 6 per cent increase from the previous year and setting the groundwork for 2024/25," stated Professor Alison Strath, Chief Pharmaceutical Officer for Scotland, in the document. "The guaranteed income from the drug tariff will remain at £80 million for the financial year, without yearly changes."

However, the current level of guaranteed minimum income has increased by £15.95 million (19 per cent) to £100 million. “The delivery of the guaranteed minimum income will be closely monitored monthly throughout the year and further action to support contractor cashflow will be considered if appropriate,” Strath added.

As per the circular, details about margin sharing arrangements will be furnished in the upcoming weeks, guided by findings from the Scottish Government's community pharmacy regular pricing inquiry report.

According to the document, community pharmacy contractors will receive a one-off payment from an agreed fund of £1.66 million. "Payment will be calculated based on the activity in the April dispensing pool. This payment will adhere to a schedule where it's processed in June but will be distributed or paid out in August. This acknowledges the absence of a drug tariff adjustment for April 2023."

Community Pharmacy Scotland described the agreement as mutually beneficial, offering a more stable financial perspective for pharmacies following a demanding 2022-23 characterised by financial, workforce, and workload pressures. "This guaranteed minimum income comes from the reimbursement aspect of our financial structure. It represents the lowest amount we consider acceptable this year from the Tariff, designed to aid the expenses of service provision throughout our financial framework,” said CPS.

"We are currently working with Scottish government to fine-tune the details of how we would handle underperformance, aiming for this to be a responsive measure to protect our cashflow,” CPS added.

The new funding agreement for 2023-24, involving over 1,200 community pharmacies, was initially announced on July 21. However, specific details weren't made public until two weeks later.

During his UCL School of Pharmacy Lecture in June, CPS CEO Professor Harry McQuillan urged UK pharmacists to prioritise 'safety of supply' over 'accuracy of supply' for patients. He emphasised investing in teams, technology, and embracing a more clinical future to ensure maximum benefits from prescribed medicines.

More For You

Imported dengue reach record high, warns UKSHA

Most dengue cases were linked to travel to Southern and South-Eastern Asia.

Getty Images

Imported dengue cases hit record high – Consult your pharmacist before you travel

The UK Health Security Agency (UKSHA) has warned that imported dengue cases in England, Wales, and Northern Ireland (EWNI) have reached their highest level since dengue surveillance began in 2009.

New data from the agency reveals that 904 dengue cases were reported among returning travellers in these countries in 2024, a sharp increase from 631 in 2023.

Keep ReadingShow less
Henry Gregg named as new NPA chief executive

Henry Gregg (left) with Sir Chris Whitty

Pic credit: Henry Gregg/X

Henry Gregg named as new NPA chief executive

The National Pharmacy Association (NPA) has announced Henry Gregg will be the organisation’s new chief executive from May.

Gregg, who is currently director of external affairs at Asthma + Lung UK, replaces Paul Rees who departed in January.

Keep ReadingShow less
Kelso Pharma continues expansion with £140M funding boost

Kelso Pharma will use the funds to support further acquisitions and expand in the UK and Europe.

Getty Images

Kelso Pharma secures over £140m of acquisition funding

Kelso Pharma has secured more than £140 million of acquisition funding to support its expansion in the UK and across Europe.

The specialty pharmaceuticals business today (27) confirmed that a proportion of the funding was used for its acquisition of ALTURiX last month, a deal that doubled the size of the company’s UK business.

Keep ReadingShow less
Community pharmacist accessing GP Connect Access Record on Cegedim Rx platform

GP Connect Access Record will make a patient’s relevant medical information available to pharmacy.

Getty Images

Cegedim Rx activates GP Connect Access Record

Community pharmacy IT supplier Cegedim Rx has made GP Connect Access Record functionality available across its clinical services platform, providing registered pharmacy professionals with enhanced access to patient medical information.

The new feature, now live on Cegedim Rx’s Pharmacy Services platform, allows community pharmacies to retrieve relevant medical data when delivering NHS clinical services.

Keep ReadingShow less
Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

Patients who purchase two prescriptions per month could save more than £110 annually with a 12-month PPC.

Getty Images

Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

The NHS Business Services Authority (NHSBSA) has published a new experimental analysis, estimating patient savings achieved from prescription prepayment certificates (PPCs), including Hormone Replacement Therapy (HRT) PPCs.

The report revealed that the number of Prescription Prepayment Certificates (PPCs) purchased has risen consistently over the past five years, with 3.3 million patients receiving NHS prescriptions under a PPC exemption in 2023/2024.

Keep ReadingShow less